A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
NCT06915246 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49
Last updated 2026-03-27
Summary
A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
Conditions
Interventions
- DRUG
-
VI-0609
Carmustine with Propylene Glycol
- DRUG
-
BiCNU
Carmustine with Ethanol
Sponsors & Collaborators
-
VIVUS LLC
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-12
- Primary Completion
- 2027-03-31
- Completion
- 2027-04-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
NCT03712202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
NCT04268706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
VELCADE,Rituximab,Cyclophosphamide and Decadron
NCT00413959 ·Status: TERMINATED ·Phase: PHASE2
-
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
NCT02278796 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
NCT00079105 ·Status: COMPLETED ·Phase: PHASE2
-
Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
NCT00004162 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
NCT03677141 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
NCT00388349 ·Status: COMPLETED ·Phase: PHASE2
-
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03583424 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
NCT00863369 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00007852 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
NCT01458366 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865 ·Status: COMPLETED ·Phase: PHASE2
-
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT02168907 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
NCT00967369 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
NCT00086801 ·Status: COMPLETED ·Phase: PHASE2
-
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
NCT02168140 ·Status: COMPLETED ·Phase: PHASE1
-
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
NCT03223610 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
NCT01035463 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
NCT00381940 ·Status: COMPLETED ·Phase: PHASE2
-
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
NCT00562978 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
NCT06649812 ·Status: RECRUITING ·Phase: PHASE2
-
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04561206 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
NCT05863845 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
NCT02292979 ·Status: COMPLETED ·Phase: PHASE2